newsfilter
← Latest News
GlobeNewswire·

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro potency data,